Halozyme (HALO) fundamentals: P/E, valuation, undervalued?
Halozyme · Health Care · ref. ETF XLV · price $109.62
In short — Halozyme trades at 32.1× earnings (P/E), 10.3× forward, with a net margin of 24.9 % and revenue growth of +48 %. Read: Cheap for the growth (P/E 10 for ~43% growth (PEG 0.2)).
Is Halozyme stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$109.62+64.5% over range
Oct 14, 25low $61.63 · high $115.22Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
71% recommend buying · 7 analysts
Valuation : Cheap for the growth — P/E 10 for ~43% growth (PEG 0.2)
Valuation
32.1
P/E (price/earnings)
10.3
Forward P/E
0.75
PEG
87.1
Price/book (P/B)
$12.4B
Market cap
3.42
EPS
Profitability & growth
24.9 %
Net margin
+48 %
Revenue growth
+43 %
Earnings growth
$2.2B
Total debt
Halozyme income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $660M | $202M | 30.6 % |
| 2023 | $829M | $282M | 34.0 % |
| 2024 | $1.0B | $444M | 43.7 % |
| 2025 | $1.4B | $317M | 22.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Halozyme's P/E and is the stock undervalued? What's a good P/E?
Halozyme's P/E is 32.1 (forward 10.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Halozyme profitable?
Halozyme has a net margin of 24.9 % (EPS 3.42). The company is profitable.
Is HALO stock expensive?
Our read: "Cheap for the growth" — P/E 10 for ~43% growth (PEG 0.2). Cross-check with growth and sector.
💬 A question about Halozyme? The JPI assistant answers using our backtest data.
Keep exploring Halozyme